Patents by Inventor Douglas Harnish

Douglas Harnish has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090215748
    Abstract: Provided are certain methods of treating at least one condition that can be treated by elevating the vitamin D receptor (VDR) activity level in a patient with at least one farnesoid X receptor (FXR) agonist.
    Type: Application
    Filed: December 19, 2008
    Publication date: August 27, 2009
    Applicant: Wyeth
    Inventor: Douglas Harnish
  • Publication number: 20090163474
    Abstract: Provided are certain methods of treating nonalcoholic fatty liver disease with farnesoid X receptor agonists. Also provided are certain methods of modulating levels of keratinocyte-derived chemokine (KC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), cytokeratin 18 (CK-18), matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-14 (MMP-14), tissue inhibitor of metalloproteinase 1 (TIMP-1), and Cytochrome P450 2E1 (CYP2E1); certain methods of identifying FXR modulators; and certain methods of treating patients with existing cholesterol gallstone disease.
    Type: Application
    Filed: October 16, 2008
    Publication date: June 25, 2009
    Applicant: Wyeth
    Inventors: Songwen Zhang, Douglas Harnish, Mark J. Evans, Juan Wang
  • Publication number: 20080300235
    Abstract: Provided are certain methods of treating at least one disease state characterized by elevated expression of the Lectin-like Oxidized Low-density Lipoprotein Receptor 1 (LOX-1) in a patient with farnesoid X receptor agonists. Also provided are certain methods of reducing expression of LOX-1 in a cell with farnesoid X receptor agonists.
    Type: Application
    Filed: May 30, 2008
    Publication date: December 4, 2008
    Applicant: Wyeth
    Inventors: Douglas Harnish, Songwen Zhang
  • Publication number: 20060252154
    Abstract: The present invention relates to an assay system and method for testing compounds for their ability to regulate the hepatic lipase (HL) promoter. In particular, the invention relates to the identification of estrogen receptor ligands having this activity.
    Type: Application
    Filed: June 21, 2006
    Publication date: November 9, 2006
    Applicant: Wyeth
    Inventors: Douglas Harnish, Marshall Scicchitano, Sotirios Karathanasis, Chu-Lai Hsiao
  • Publication number: 20060111421
    Abstract: The present invention concerns a method of treatment or prevention of myocardial ischemia-reperfusion injury by diagnosing that a person is in need of treatment or prevention of myocardial ischemia-reperfusion injury and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-?, estrogen receptor ER-?, or both ER-? and ER-? estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.
    Type: Application
    Filed: August 17, 2005
    Publication date: May 25, 2006
    Applicant: Wyeth
    Inventors: Christopher Chadwick, Douglas Harnish
  • Publication number: 20050256132
    Abstract: The present invention provides methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome by modulating NF-?B transcription with ligands that interact with the estrogen receptor, preferably in the absence of classic estrogenic activity.
    Type: Application
    Filed: April 27, 2005
    Publication date: November 17, 2005
    Applicant: Wyeth
    Inventors: Thomas Caggiano, Antony Brazzale, William Moore, Callain Kim, Douglas Harnish
  • Publication number: 20050221328
    Abstract: Methods of identifying agents effective as inhibitors of short heterodimer protein (SHP) and farnesoid X receptor (FXR) and promoters, cell lines and vectors used in said methods. Methods of preparing and using the agents effective as inhibitors of short heterodimer protein (SHP), including methods of using same to prevent and/or treat a condition associated with inflammatory gene activity and/or cholesterol biosynthesis in a subject. Agents effective as inhibitors of short heterodimer protein (SHP) and farnesoid X receptor (FXR) and compositions comprising same, including compositions effective in reducing inflammatory gene activity and/or cholesterol biosynthesis in a subject.
    Type: Application
    Filed: June 13, 2003
    Publication date: October 6, 2005
    Inventors: Mark Evans, Douglas Harnish
  • Publication number: 20050119276
    Abstract: The present invention concerns a method of treating inflammatory bowel disease by diagnosing that a person is in need of treatment for inflammatory bowel disease and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-?, estrogen receptor ER-?, or both ER-? and ER-? estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.
    Type: Application
    Filed: September 23, 2004
    Publication date: June 2, 2005
    Applicant: Wyeth
    Inventors: Douglas Harnish, Christopher Chadwick, James Keith
  • Publication number: 20050119324
    Abstract: The present invention concerns a method of treating atherosclerosis by diagnosing that a person is in need of treatment for atherosclerosis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-?, estrogen receptor ER-?, or both ER-? and ER-? estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.
    Type: Application
    Filed: September 23, 2004
    Publication date: June 2, 2005
    Applicant: Wyeth
    Inventors: Douglas Harnish, Christopher Chadwick
  • Publication number: 20050113405
    Abstract: The present invention concerns a method of treating rheumatoid arthritis by diagnosing that a person is in need of treatment for rheumatoid arthritis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-?, estrogen receptor ER-?, or both ER-? and ER-? estrogen receptors with a substantial absence of creatine kinase stimulation. In certain embodiments, the administration is with a substantial absence of uterotropic activity.
    Type: Application
    Filed: September 23, 2004
    Publication date: May 26, 2005
    Applicant: Wyeth
    Inventors: Douglas Harnish, Christopher Chadwick, James Keith